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Background
RTS,S is a malaria vaccine directed at the pre-erythrocy-
tic stage of Plasmodium falciparum, and is currently in
late-stage Phase III clinical trials at multiple sites across
Africa. Modeling and simulation have been used to pre-
dict the public health impact (PHI) of RTS,S but previous
exercises had access to limited trial data and did not pro-
vide country-specific results. PHI is sensitive to many
assumptions including vaccine profile and underlying
country specific inputs.
Materials and methods
We simulated the numbers of cases and deaths averted by
RTS,S if rolled out in each of 43 malaria endemic countries
in sub-Saharan Africa. Predictions were made for different
transmission profiles, different levels of access to care for
malaria cases, and four different immunisation schedules,
with varying initial efficacies and decay rates of vaccine effi-
cacy. Country-specific predictions were made via weighted
averages over the database of predictions, with weights esti-
mated from country-specific data. These included preva-
lence data from the Malaria Atlas Project, access to care
from Demographic and Health Surveys, country level esti-
mates of patient adherence and system compliance, immu-
nization coverage from UN/WHO, and demographic
projections from the UN. Sensitivity analysis was carried
out to determine the robustness of the predictions of aver-
age impact and main drivers of uncertainty in these.
Results and conclusions
A pre-erythrocytic vaccine is unlikely to completely protect
vaccinated individuals against malaria disease but overall
PHI will probably compare favourably with that of other
vaccines in routine programs. Currently only short follow
up of RTS,S Phase III trial data is available and thus uncer-
tainty in overall PHI remains mainly driven by uncertainty
in the vaccine profile, especially in the rate of decay of the
protective effects. There will be considerable variation
between countries in PHI, with the main driver of this
variation being the underlying levels of transmission and
disease burden.
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